NYSE:PFE - Pfizer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$44.06 +0.31 (+0.71 %)
(As of 09/23/2018 03:08 AM ET)
Previous Close$44.06
Today's Range$43.61 - $44.1950
52-Week Range$33.20 - $44.19
Volume34.79 million shs
Average Volume17.51 million shs
Market Capitalization$260.44 billion
P/E Ratio16.63
Dividend Yield3.11%
Beta0.96
Pfizer logoPfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; BioNTech AG for the research and development of mRNA-based vaccines for the prevention of influenza; and Neofluidics, LLC to develop a microfluidics-based platform, as well as development agreement with Antares Pharma, Inc. to develop a combination drug device rescue pen. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:PFE
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.41
Current Ratio1.16
Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio16.63
Forward P/E Ratio14.74
P/E Growth2.21

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.99
Cash Flow$3.7755 per share
Price / Cash11.67
Book Value$12.02 per share
Price / Book3.67

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins42.35%
Return on Equity25.35%
Return on Assets10.29%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000
Market Cap$260.44 billion

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 28th. Stockholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has approved a share repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. The biopharmaceutical company had revenue of $13.47 billion for the quarter, compared to analysts' expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

What price target have analysts set for PFE?

20 equities research analysts have issued 1 year price targets for Pfizer's shares. Their forecasts range from $37.00 to $47.00. On average, they expect Pfizer's share price to reach $42.1765 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. Cantor Fitzgerald analysts commented, ". After speaking with five oncologists, we see two growth drivers for Ibrance that represent meaningful upside to consensus sales and our numbers. These opportunities include: OUS expansion and the use of Ibrance in the earlier-stage adjuvant setting. Our discussions focused on answering the following questions: (1) What is the remaining growth/market penetration opportunity for CDK 4/6s in the currently approved indications?; (2) How much share erosion can we expect from other CDK 4/6s such as How high is physician conviction for PALLAS and How much will positive outcomes increase usage? Below we highlight our key takeaways." (9/13/2018)
  • 2. According to Zacks Investment Research, "Pfizer beat estimates for both earnings and sales in the second quarter. Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance.  Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential.  Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has four potential medicines under FDA’s priority review. The shares have outperformed the industry this year so far." (8/6/2018)

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 48,507,825 shares, a decrease of 7.1% from the August 15th total of 52,192,249 shares. Based on an average trading volume of 18,845,697 shares, the short-interest ratio is presently 2.6 days. Currently, 0.8% of the company's stock are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
  • Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), Northern Trust Corp (1.28%), Bank of New York Mellon Corp (1.14%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%) and Morgan Stanley (0.91%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which institutional investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Royal London Asset Management Ltd., Natixis and Fisher Asset Management LLC. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $44.06.

How big of a company is Pfizer?

Pfizer has a market capitalization of $260.44 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,169 (Vote Outperform)
Underperform Votes:  640 (Vote Underperform)
Total Votes:  1,809
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel